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Meeting report
Beatson International Cancer Conference - Cancer: from
Pedigree to Protein
VG Brunton' and N Keith2
'Beatson Institute for Cancer Research and 2CRC Department of Medical Oncology, CRC Beatson Laboratories, Garscube Estate, Switchback Road, Bearsden,
Glasgow G61 1 BD, UK
MOLECULAR MEDICINE
Using genetic and cellular information to generate new therapies
for cancer is a major challenge. Indeed, a criticism of much cancer
research is that there is little point in finding the cause of the
disease if this information offers no hope for disease prevention or
treatment. However, the turning point has arrived and, as we
progress towards the 21st century, the past 40 years of conven-
tional cancer therapies are becoming augmented by a new genera-
tion of innovative molecular therapeutics founded on an
understanding of gene function. A recent meeting, 'Cancer: from
Pedigree to Protein', sponsored by the Cancer Research Campaign
and the Association for International Cancer Research and hosted
by the Beatson Institute for Cancer Research in Glasgow, provided
an opportunity for scientists from a number of diverse research
fields, spanning basic cancer genetics through to translational
research, to highlight the vast richness of resources available on
which to base future therapeutic strategies.
MICE, MEN AND CELLULAR SENESCENCE
Using families to study genetic traits has a long and fruitful
history, from Mendel's peas to the cloning of BRCAJ and BRCA2.
Indeed, the study of BRCAJ provides a perfect example of how
cancer research spans from pedigree to protein. However, one of
the most interesting families discussed at the meeting was that of
mice in which the gene for the essential RNA component of the
telomerase enzyme has been knocked out (DePinho, New York).
Interestingly, the homozygous null mice are viable and fertile.
However, with advancing generations there are progressive
defects to the haematopoietic system and, by the sixth generation,
fertility has been reduced to a level at which no successful matings
occur. Consistent with a role for telomere length and telomerase
activity in the normal proliferative lifespan of cells, Wright
(Dallas) described the extension of proliferative lifespan by the
experimental elongation of telomeres. Thus it appears that telom-
erase is essential to prevent cellular senescence, but what of cancer
development? The reactivation of telomerase in cancer cells has
taken on a central role in tumour development, yet there is little
direct evidence to prove it is necessary for tumour initiation or
progression. Cell lines derived from the null mice can indeed form
tumours, suggesting, at least in the mouse, that tumour develop-
ment is not necessarily dependent on telomerase; the link between
telomerase activation and tumour progression therefore remains
largely correlative.
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The question is, now, what percentage of human tumours are
truly immortal and have escaped senesence? Together, Wright
(Dallas), Pereira-Smith (Houston) and Parkinson (Glasgow)
discussed the combination of genetic events and environmental
influences that may combine to overcome senescence. New loci on
chromosomes 4 and 7 have been identified as harbouring senes-
cence-related genes in addition to relatively well-characterized
genes such as RB, p53 and p16. This overlap between senescence
and tumour-suppressor genes is intriguing and certainly suggests
that the pathways involved in tumour development and over-
coming cellular senescence may be convergent.
TUMOUR CELL BEHAVIOUR
In order to develop new therapeutic agents one must first identify a
potential target; Information on the function of such a target and
differences between tumour and normal cell behaviour are instru-
mental in determining whether the chosen target will prove to be
viable. How tumour cells interact with their environment plays a
crucial part in tumour cell biology, and our increasing knowledge
on how cells can integrate signals that regulate cell cycle informa-
tion and apoptosis, on one hand, or migration and invasion, on the
other, will help the development of new strategies. A number of
speakers addressed this issue. For example, the GI phase of the cell
cycle is jointly regulated by mitogenic growth factors and the
extracellular matrix (ECM) (Assoian, Miami). This joint regula-
tion was shown to be a co-ordinated effect of growth factors and
the ECM on the GI phase cyclin-dependent kinases. Assoian
provided evidence for both integrated pathways and parallel,
independent pathways from growth factors and ECM signals.
Focal adhesions are sites where clustered integrins provide
adhesion on the outside to the ECM and attachment to the actin
cytoskeleton at their cytoplasmic face. Their formation is under
the control of the small G protein Rho. Rho appears to promote
assembly of focal adhesions by initiating several synergistic path-
ways, and Burridge (Chapel Hill) presented data supportive of a
role for Rho in the stimulation of myosin filament assembly. The
resultant contractility of the cells exerts tension on the integrins,
clustering them at points ofECM contact and initiating focal adhe-
sion assembly. The regulation of focal adhesion turnover plays a
key role in cell motility, and it is of interest that Tiaml, an activator
of Rac, which is a Rho family member, was identified as a gene
involved in invasion and metastasis (van Leeuwen, Amsterdam).
Their data suggest that the signalling pathways controlled by Rac
and Rho, which participate in the co-ordination of cell movement,
play an important role in tumour invasion and metastasis.
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Another key step in the invasive process is the degradation of
the ECM by proteolytic enzymes, such as metalloproteinases
and the urokinase-type plasminogen activation system. Dano
(Copenhagen) presented data that revealed that in many cases the
components of these enzyme systems were not found in the
tumour cells themselves but in the surrounding stromal tissue. This
highlights another important issue - that the tumour cell environ-
ment plays a crucial role in tumour cell survival. Another example
was provided by Frisch (La Jolla) who demonstrated that loss of
an integrin signal from the ECM in epithelial cells renders them
sensitive to anoikis. This is the term given to the phenomenon
when epithelial cells undergo apoptosis when they lose contact
with the ECM. He believes that this could protect against
neoplasia by eliminating shed epithelial cells before they can
colonize elsewhere.
THERAPEUTIC STRATEGIES
The importance of translational research in the cancer field is
becoming increasingly evident, and a number of speakers high-
lighted this issue with respect to their own line of research. Of note
was the fact that the majority of these researchers had industrial
collaborators for their preclinical studies. Surely such
academic/industrial collaborations can only aid the progress of
novel therapeutics and is something that should be encouraged.
Both Lane (Dundee) and Marshall (London) also emphasized
another important aspect of this approach - validation of the
target. The potential targets ranged from cell surface receptors and
intermediate signalling proteins through to tumour-suppressor
genes and the approaches included enzyme inhibition and protein-
protein interaction inhibition.
Amplification and rearrangements of the epidermal growth
factor (EGF) receptor are often seen in glioblastoma, and Cavenee
(La Jolla) described work on a mutated EGF receptor with a dele-
tion in the extracellular domain that cannot bind the ligand. This
receptor is constitutively phosphorylated and is not regulated by
EGF. Infection of glioblastoma cells with this mutated receptor
leads to increased tumour growth after stereotactic injection into
mice. This mutated receptor represents a good therapeutic target as
its cell surface location means that access to therapeutic agents is
easier than for intracellular targets, and the rearrangement is
specific to tumours. Screening inhibitors identified a tyrphostin
compound that preferentially inhibits the deleted EGF receptor
tyrosine kinase, and further structure activity relationship studies
are under way to overcome problems with solubility. Signalling
through the transforming growth factor beta (TGF-P) receptor was
also discussed (Massague, New York). Intermediate proteins in this
pathway include the Smad family members, which heterodimerize
in response to ligand. These heterodimers can accumulate in the
nucleus where they associate with DNA binding partners and
initiate transcriptional activity. Mutations in the Smad proteins are
found in a large number of tumour types, and these affect dimer
formation and transport to the nucleus. The crystal structure of one
Smad protein DPC4 has been resolved and sheds light on the mech-
anism of Smad oligomerization and its disruption in cancer.
Marshall (London) discussed his work on another signalling
intermediate, the small G protein Ras and outlined the rationale for
Ras as a therapeutic target. Not only is Ras mutated in a large
number of human tumours but Ras may also be a target in tumours
in which normal Ras function is required for the proliferation of
cells rendered malignant by overexpression of receptor tyrosine
kinases. A number of approaches to inhibit Ras function are
possible, such as inhibition of farnesyl transferase processing of
Ras proteins, blocking GTP binding and inhibition of signalling
through Ras pathways. Increased knowledge of the Ras signalling
pathway has identified key candidates for development of the
latter approach (such as Raf and MAP kinase) and Marshall
outlined two methods for screening inhibitors of the Ras pathway
that are being undertaken. Firstly, automated in vitro enzyme
screens using recombinant Raf and MAP kinase and, secondly, use
of yeast expressing the mammalian genes for Raf and MAP kinase
as an in vivo screen using the mating response transcription
activation as a read out.
Mutations in the tumour-suppressorp53 are the most commonly
found genetic alterations in human cancers, and Lane (Dundee)
presented his approach to restore p53 function in tumours. mdm2
is an oncogene that is amplified/overexpressed in a variety of solid
tumours in which wild-type p53 is present and it prevents p53
function. They have developed peptides that mimic the binding
site for mdm2 and can displace mdm2 from p53 in vitro. In cells,
the problem with handling peptides has been overcome by the
use of thioredoxin-insert proteins (TIPs) in which the peptide
sequences are inserted into the thioredoxin/active site and trans-
ported into the cells. Thus an agent has been developed that targets
mdm2-p53 interactions and mimics conventional therapeutics
without causing DNA damage to activate p53.
Another example of how disruption of protein-protein interac-
tions may lead to a therapeutic agent came from studies on the
regulation of the transcription factor E2F. In this case, peptides
that block the formation of E2F-DP-1 heterodimers, which regu-
late the G1/S phase transition, cause apoptosis in tumour cells
(La Thangue, Glasgow). Other aspects of cell cycle regulation
discussed were the regulation of D type cyclins. The elegant in
vitro analysis of cyclin D phosphorylation (Sherr, Memphis)
pointed out possible future targets for molecules able to modulate
the phosphorylation of such key regulatory molecules. It is clear
that a number of different approaches are being developed for the
generation of new therapeutic agents, however one important
point was highlighted by Bartek (Copenhagen). In cancer cells,
there are aberrations in a few key regulatory pathways, for
example restriction point control, genome integrity control, cell
death pathways, cell-cell matrix interactions, and it may be neces-
sary to target more than one regulatory pathway to achieve a ther-
apeutic effect. In human carcinoma cells, overexpression of p53
and the cell cycle regulator p16, but not p53 on its own, induced
apoptotic cell death in tumours, which Bartek believes could be
the basis for the development of a new strategy for cancer gene
therapy. This theme was continued by Land (London) who
addressed the question of oncogene co-operation, when dominant
negative p53 and Myc co-operate with Raf via distinct mecha-
nisms, although the two pathways converge on the regulation of
cyclin/cdk activities.
Another potential therapeutic approach discussed was the intro-
duction of the adenovirus Ela protein, as a master programmer of
the epithelial phenotype, into tumour cells (Frisch, La Jolla). This
renders the tumour cells sensitive to anoikis, anchorage dependent
and non-tumorigenic. Frisch is currently exploring the therapeutic
potential of this seemingly broad-range tumour-suppressor protein.
A number of clinical studies were described in which novel
approaches to therapy have been used based on an increased
knowledge of the genetics and biology of the diseases. Ganly
(Glasgow) described a phase 1 trial that is under way using an
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adenovirus targeted to mutant p53 in patients with squamous cell
carcinoma of the head and neck. In this disease, more than 80% of
recurrent tumours have p53 mutations. To date, 27 patients have
entered the trial and have experienced limited toxicities. Although
no complete or partial responses to the complete tumour burden
were seen, necrosis and regression of the injected tumours were
observed and a multicentre phase 2 trial is planned.
BRCAI A PARADIGM FOR CANCER THERAPY?
Returning to the major theme of the meeting, there can be no better
example of a field of study that encompasses 'Cancer: from
Pedigree to Protein', than BRCAJ. Having discussed pedigree
studies and the relevance of specific mutations (Peto, Surrey), we
were treated to lively debate on the function and cellular location
of the BRCA1 protein (Holt, Nashville; Sherr, Memphis; Black,
Glasgow). As to a consensus of opinion on this, there was none!
Yet despite the incomplete information on BRCA1 function, Holt
(Nashville) presented some very impressive clinical studies on the
successful use of retroviral gene transfer of BRCAJ in ovarian
cancer. Thus, although the mechanism of treatment may not be
completely understood at present, the parallel progress of the labo-
ratory based and clinical studies has certainly provided optimism
for new molecular therapies.
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